Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.

Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P.

PLoS Med. 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep.

2.

Introducing risk inequality metrics in tuberculosis policy development.

Gomes MGM, Oliveira JF, Bertolde A, Ayabina D, Nguyen TA, Maciel EL, Duarte R, Nguyen BH, Shete PB, Lienhardt C.

Nat Commun. 2019 Jun 6;10(1):2480. doi: 10.1038/s41467-019-10447-y.

3.

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.

Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C.

Emerg Infect Dis. 2019 May;25(5):936-943. doi: 10.3201/eid2505.181823.

4.

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ.

PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.

5.

Advances in clinical trial design for development of new TB treatments: A call for innovation.

Lienhardt C, Nahid P.

PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.

6.

Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates.

Reis-Santos B, Shete P, Bertolde A, Sales CM, Sanchez MN, Arakaki-Sanchez D, Andrade KB, Gomes MGM, Boccia D, Lienhardt C, Maciel EL.

PLoS One. 2019 Feb 22;14(2):e0212617. doi: 10.1371/journal.pone.0212617. eCollection 2019.

7.

Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study.

Oliosi JGN, Reis-Santos B, Locatelli RL, Sales CMM, da Silva Filho WG, da Silva KC, Sanchez MN, de Andrade KVF, de Araújo GS, Shete PB, Pereira SM, Riley LW, Lienhardt C, Maciel ELN.

Lancet Glob Health. 2019 Feb;7(2):e219-e226. doi: 10.1016/S2214-109X(18)30478-9. Epub 2018 Dec 21.

8.

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1.

PMID:
30429542
9.

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5. Erratum in: Nat Med. 2019 Jan;25(1):190.

10.

Analysis of the clinical antibacterial and antituberculosis pipeline.

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S.

Lancet Infect Dis. 2019 Feb;19(2):e40-e50. doi: 10.1016/S1473-3099(18)30513-9. Epub 2018 Oct 15. Review.

PMID:
30337260
11.

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.

Kik SV, Schumacher S, Cirillo DM, Churchyard G, Boehme C, Goletti D, Rangaka MX, Denkinger CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F.

Eur Respir J. 2018 Oct 25;52(4). pii: 1800946. doi: 10.1183/13993003.00946-2018. Print 2018 Oct.

PMID:
30139776
12.

Defining a migrant-inclusive tuberculosis research agenda to end TB.

Shete PB, Boccia D, Dhavan P, Gebreselassie N, Lönnroth K, Marks S, Matteelli A, Posey DL, van der Werf MJ, Winston CA, Lienhardt C.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):835-843. doi: 10.5588/ijtld.17.0503. Review. Erratum in: Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1244.

13.

A bibliometric analysis of tuberculosis research, 2007-2016.

Nafade V, Nash M, Huddart S, Pande T, Gebreselassie N, Lienhardt C, Pai M.

PLoS One. 2018 Jun 25;13(6):e0199706. doi: 10.1371/journal.pone.0199706. eCollection 2018.

14.

Would pan-tuberculosis treatment regimens be cost-effective?

Kendall EA, Brigden G, Lienhardt C, Dowdy DW.

Lancet Respir Med. 2018 Jul;6(7):486-488. doi: 10.1016/S2213-2600(18)30197-8. Epub 2018 May 31. Review. No abstract available.

15.

Mercury Biomagnification Through a Coral Reef Ecosystem.

Rumbold DG, Lienhardt CT, Parsons ML.

Arch Environ Contam Toxicol. 2018 Jul;75(1):121-133. doi: 10.1007/s00244-018-0523-0. Epub 2018 Apr 19.

PMID:
29675668
16.

Priorities for global political momentum to end TB: a critical point in time.

Kasaeva T, Baddeley A, Floyd K, Jaramillo E, Lienhardt C, Nishikiori N, Weil DE, Weyer K, Zignol M.

BMJ Glob Health. 2018 Mar 23;3(2):e000830. doi: 10.1136/bmjgh-2018-000830. eCollection 2018. No abstract available.

17.

Tuberculosis research and development: seeding the future.

Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):242-244. doi: 10.1016/S2213-2600(18)30050-X. No abstract available.

PMID:
29595503
18.

Harnessing the Power of Data to Guide Local Action and End Tuberculosis.

Sismanidis C, Shete PB, Lienhardt C, Floyd K, Raviglione M.

J Infect Dis. 2017 Nov 6;216(suppl_7):S669-S672. doi: 10.1093/infdis/jix374. No abstract available.

19.

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.

Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A, Perronne C, Lienhardt C, McIlleron H, Fielding K.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e01834-16. doi: 10.1128/AAC.01834-16. Print 2017 Jul.

20.

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602308. doi: 10.1183/13993003.02308-2016. Print 2017 Mar.

21.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

22.

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW.

PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.

23.

From latent to patent: rethinking prediction of tuberculosis.

Cobelens F, Kik S, Esmail H, Cirillo DM, Lienhardt C, Matteelli A.

Lancet Respir Med. 2017 Apr;5(4):243-244. doi: 10.1016/S2213-2600(16)30419-2. Epub 2016 Dec 22. No abstract available.

PMID:
28017341
24.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

25.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.

26.

Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.

Lienhardt C, Kraigsley AM, Sizemore CF.

Clin Infect Dis. 2016 Aug 1;63(3):370-5. doi: 10.1093/cid/ciw250. Epub 2016 Jun 5.

27.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F; RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative).

PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016. Review.

28.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

29.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.

Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M.

PLoS Med. 2016 Mar 2;13(3):e1001965. doi: 10.1371/journal.pmed.1001965. eCollection 2016 Mar. Review. No abstract available.

30.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

31.

First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.

Ejo M, Gehre F, Barry MD, Sow O, Bah NM, Camara M, Bah B, Uwizeye C, Nduwamahoro E, Fissette K, De Rijk P, Merle C, Olliaro P, Burgos M, Lienhardt C, Rigouts L, de Jong BC.

Infect Genet Evol. 2015 Jul;33:314-9. doi: 10.1016/j.meegid.2015.05.022. Epub 2015 May 21.

32.

WHO's new end TB strategy.

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M; for WHO's Global TB Programme.

Lancet. 2015 May 2;385(9979):1799-1801. doi: 10.1016/S0140-6736(15)60570-0. Epub 2015 Mar 24. No abstract available.

PMID:
25814376
33.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

34.

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation.

Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC.

Eur Respir J. 2014 Dec;44(6):1412-7. doi: 10.1183/09031936.00132114. No abstract available.

35.

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.

Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, McIlleron H, Lienhardt C, Pym A.

BMC Pharmacol Toxicol. 2014 Nov 19;15:61. doi: 10.1186/2050-6511-15-61.

36.

A four-month gatifloxacin-containing regimen for treating tuberculosis.

Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project.

N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817. Erratum in: N Engl J Med. 2015 Apr 23;372(17):1677.

37.

Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.

Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, Kim SJ, Enarson DA, Jindani A, Lienhardt C; Study C team.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1252-4. doi: 10.5588/ijtld.14.0281.

PMID:
25216842
38.

Fundamental research is the key to eliminating TB.

Lienhardt C.

Nature. 2014 Mar 27;507(7493):401. doi: 10.1038/507401a. No abstract available.

PMID:
24670725
39.

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD.

PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014.

40.

Methodological and reporting quality of systematic reviews on tuberculosis.

Nicolau I, Ling D, Tian L, Lienhardt C, Pai M.

Int J Tuberc Lung Dis. 2013 Sep;17(9):1160-9. doi: 10.5588/ijtld.13.0050. Epub 2013 Jun 27.

PMID:
23809432
41.

The ethics of a clinical trial when the protocol clashes with international guidelines.

Lan NT, Thu NT, Duc NH, Lan NN, Lien TT, Dung NH, Taburet AM, Laureillard D, Borand L, Quillet C, Lagarde D, Pym A, Connolly C, Lienhardt C, Rekacewicz C, Harries AD.

Public Health Action. 2013 Jun 21;3(2):97-102. doi: 10.5588/pha.13.0017.

42.

Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.

Smythe W, Merle CS, Rustomjee R, Gninafon M, Lo MB, Bah-Sow O, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US.

Antimicrob Agents Chemother. 2013 Sep;57(9):4164-71. doi: 10.1128/AAC.00479-13. Epub 2013 Jun 17.

43.

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M.

Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Review.

44.

Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review.

Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C.

PLoS Med. 2012;9(12):e1001358. doi: 10.1371/journal.pmed.1001358. Epub 2012 Dec 18. Review.

45.

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.

Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F; Research Excellence to Stop TB Resistance (RESIST-TB); Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup.

Int J Tuberc Lung Dis. 2013 Feb;17(2):146-52. doi: 10.5588/ijtld.12.0017. Epub 2012 Dec 4. Review.

PMID:
23211610
46.

Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses.

Nicolau I, Ling D, Tian L, Lienhardt C, Pai M.

PLoS One. 2012;7(7):e42479. doi: 10.1371/journal.pone.0042479. Epub 2012 Jul 27.

47.

Detection and treatment of subclinical tuberculosis.

Robertson BD, Altmann D, Barry C, Bishai B, Cole S, Dick T, Duncan K, Dye C, Ehrt S, Esmail H, Flynn J, Hafner R, Handley G, Hanekom W, van Helden P, Kaplan G, Kaufmann SH, Kim P, Lienhardt C, Mizrahi V, Rubin E, Schnappinger D, Sherman D, Thole J, Vandal O, Walzl G, Warner D, Wilkinson R, Young D.

Tuberculosis (Edinb). 2012 Nov;92(6):447-52. doi: 10.1016/j.tube.2012.06.004. Epub 2012 Jul 21.

48.

Key issues in the clinical development and implementation of TB vaccines in South Africa.

Rustomjee R, Mcleod R, Hanekom W, Steel G, Mahomed H, Hawkridge A, Welte A, Sinanovic E, Loots G, Grobler A, Mvusi L, Gray G, Hesseling A, Ginsberg A, Lienhardt C, Shea J, Tong X, Lockhart S, Churchyard GJ.

Tuberculosis (Edinb). 2012 Sep;92(5):359-64. doi: 10.1016/j.tube.2012.05.001. Epub 2012 Jun 12.

PMID:
22698868
49.

Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A.

Lancet. 2012 May 19;379(9829):1902-13. doi: 10.1016/S0140-6736(12)60727-2. Review. Erratum in: Lancet. 2012 Jun 16;379(9833):2242.

PMID:
22608339
50.

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project.

Merle CS, Sismanidis C, Sow OB, Gninafon M, Horton J, Lapujade O, Lo MB, Mitchinson DA, Perronne C, Portaels F, Odhiambo J, Olliaro P, Rustomjee R, Lienhardt C, Fielding K.

Trials. 2012 May 18;13:61. doi: 10.1186/1745-6215-13-61.

Supplemental Content

Loading ...
Support Center